Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo Survival · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 62 participants | Moderate |
Summary of findings ‐ monotherapy: lumacaftor vs placebo Quality of life ‐ CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 85 participants | Low |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo Quality of life: total score · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo Quality of life: respiratory domain · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 59 participants | Moderate |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo Adverse events · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 61 participants | Low |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone Survival · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 9 studies · 1132 participants | Low |
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone Quality of life: total score · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 5 studies · 946 participants | Low |
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 5 studies · 944 participants | Low |
Summary of findings ‐ monotherapy: lumacaftor vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 5 studies · 944 participants | Low |
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone Adverse events: most commonly occurring events (occurring in at least 10% of participants) · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 8 studies · 1057 participants | Moderate |
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 506 participants | Moderate |
Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control Survival · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 4 studies · 634 participants | Moderate |
Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 382 participants | Moderate |
Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control FEV1 (% predicted): relative change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 6 participants | Ungraded |
Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control FEV1 (% predicted): absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 382 participants | Moderate |
Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 4 studies · 634 participants | Moderate |
Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: lumacaftor vs placebo FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 61 participants | Moderate |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control Survival · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 3 studies · 603 participants | High |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 3 studies · 599 participants | Moderate |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control FEV1 (% predicted): relative change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 3 studies · 603 participants | Moderate |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control FEV1 (% predicted): absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 2 studies · 578 participants | Moderate |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 3 studies · 603 participants | Moderate |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) Survival · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 258 participants | Moderate |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) Quality of life: total score · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: lumacaftor vs placebo Adverse events · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 2 studies · 115 participants | Very low |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) FEV1 (% predicted): relative change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) FEV1 (% predicted): absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 258 participants | Moderate |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) Adverse events: number of participants with treatment‐emergent adverse events · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | OR 1.04 [0.53, 2.04] | 1 study · 258 participants | Moderate |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) Time to first pulmonary exacerbation · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo Survival · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 55 participants | Low |
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo Quality of life: total score · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 55 participants | Low |
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo FEV1 (% predicted): relative change from baseline · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 55 participants | Low |
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo FEV1 (% predicted): absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 55 participants | Low |
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo Adverse events · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 55 participants | Low |
Summary of findings ‐ monotherapy: lumacaftor vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo Time to first pulmonary exacerbation · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo Survival · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | 1 study · 76 participants | Low |
Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo Quality of life: total score · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |